Competencies expected of the graduating fellow
- Defend LAAC versus continued DOAC using absolute thromboembolic, bleeding, procedural, and competing-mortality risk.
- Reconstruct the LAA in three dimensions and convert imaging into a puncture, sheath, device, and bailout plan.
- Explain how plug and lobe-disc systems achieve fixation and why each fails in specific anatomies.
- Perform a geometry-driven transseptal puncture and recognize when the puncture—not the device—is the problem.
- Apply device-specific release criteria without substituting a generic “looks good” assessment.
- Recognize tamponade, embolization, air embolism, DRT, and clinically important leak before instability becomes irreversible.
- Choose a post-implant regimen based on label, trial evidence, anatomy, bleeding phenotype, and surveillance findings.
- Critically appraise LAAC trials by comparator, generation, endpoint construction, noninferiority margin, and exposure to post-procedure therapy.
Mechanistic rationale—and its limits
The LAA is an embryologically distinct, highly compliant chamber with pectinate muscles, variable lobes, and flow patterns that become progressively unfavorable with atrial myopathy and AF. Stasis, endothelial dysfunction, inflammation, hypercoagulability, reduced appendage emptying velocity, spontaneous echo contrast, and complex trabeculation converge to create thrombus risk.
LAAC prevents embolization from the excluded appendage; it does not modify systemic thrombogenicity.
The benefit is time-dependent: an up-front procedure and healing phase substitute for years of anticoagulant exposure.
Aortic, ventricular, carotid, paradoxical, small-vessel, and noncardioembolic stroke mechanisms remain.
Why “90% of AF thrombi arise in the LAA” must be used carefully
The often-cited proportion comes largely from surgical and autopsy series and varies with rheumatic disease, imaging, and patient phenotype. The proper inference is not that all AF-related stroke is appendage-mediated; it is that the LAA is a dominant, mechanically addressable source in nonvalvular AF.
Guidelines, candidacy, and shared decision-making
Contemporary guideline position
| Source | Recommendation | Practical meaning |
|---|---|---|
| 2023 ACC/AHA/ACCP/HRS AF guideline | Class 2a For CHA₂DS₂-VASc ≥2 with a nonreversible contraindication to long-term OAC, percutaneous LAAO is reasonable. | A durable, clinically meaningful OAC contraindication supports LAAC. |
| 2023 ACC/AHA/ACCP/HRS AF guideline | Class 2b With moderate-high stroke risk and high major-bleeding risk on OAC, LAAO may be a reasonable alternative based on preference, with recognition that OAC evidence is more extensive. | Preference alone is not enough; quantify bleeding risk and disclose the evidence asymmetry. |
| 2025 SCAI/HRS LAAC guideline | Supports LAAC over no therapy in NVAF patients with an OAC contraindication; suggests either OAC or DAPT after LAAC and follow-up imaging for DRT/PDL. | Many recommendations are conditional because comparative evidence remains low certainty. |
Read the 2023 AF guideline and the open-access 2025 SCAI/HRS guideline.
A four-domain selection model
CHA₂DS₂-VASc components, prior stroke pattern, AF burden only as context, atrial myopathy, LV dysfunction, vascular disease, competing embolic sources.
Site, severity, recurrence, reversibility, transfusion, intracranial pathology, angiodysplasia, renal/liver dysfunction, falls, concomitant antiplatelets.
Life expectancy, frailty, LAA anatomy, septal access, venous access, anesthesia, renal function, esophageal disease, ability to receive rescue therapy.
Short-term antithrombotic tolerance, medication adherence, access to 45–90-day imaging, willingness to treat DRT, and continuity of care.
Contraindications and red flags
| Do not proceed today | Usually outside routine evidence | Needs individualized strategy |
|---|---|---|
| Active LAA/LA thrombus; active infection/endocarditis; no safe venous or transseptal path; incompatible anatomy; inability to tolerate any necessary peri-implant antithrombotic therapy. | Mechanical valve; moderate-severe rheumatic mitral stenosis; low stroke risk; very short life expectancy; closure solely because AF was ablated successfully. | Severe CKD/ESRD; thrombophilia; active cancer; prior surgical clip/ligation with remnant; prior septal occluder; extreme frailty; active recurrent bleeding. |
Anatomy that changes the procedure
The ostium is a virtual plane between the left lateral ridge and the inferolateral mitral annular region. The landing zone is device-defined rather than universal. The left circumflex artery and great cardiac vein course near the inferior ostial region; the left superior pulmonary vein lies behind the ridge; thin distal lobes are vulnerable to perforation.
Ellipticity, orientation, ridge thickness, relation to mitral annulus, and degree of proximal funneling determine cover and shoulder.
Measure where the device will exert radial or anchor force—not where a convenient 2-D caliper fits.
Depth is along the intended device axis. A long oblique 2-D measurement can overstate deployable depth.
Early chicken-wing bends, bilobed anatomy, and posterior lobes change wire position and sheath alignment.
Heavy pectinate burden may impede full expansion, obscure angiography, or create apparent gaps.
Avoid pulmonary-vein impingement, mitral interaction, excessive disc protrusion, and deep distal trauma.
Morphology names are shorthand, not a sizing method
“Chicken wing,” “windsock,” “cactus,” and “cauliflower” have imperfect reproducibility. For each case, describe the ostial orientation, maximum/minimum landing-zone dimensions, perimeter, area, depth along implant axis, bend distance, dominant lobe, secondary lobes, and coaxial fluoroscopic projection.
Imaging: turn anatomy into an executable plan
TEE protocol
- Survey LA and LAA for thrombus with optimized gain, depth, focus, and multiple planes; distinguish dense spontaneous echo contrast/sludge from organized thrombus.
- Acquire at approximately 0°, 45°, 90°, and 135°; sweep rather than capture one frozen frame. Record the largest ostial and device-specific landing-zone diameter.
- Measure depth from the intended landing zone toward the dominant lobe along the expected delivery axis.
- Document pulmonary venous flow, mitral function, interatrial septal thickness/mobility, prior septal devices, and baseline pericardial space.
- Use biplane/3-D imaging when available to expose ellipticity and off-axis measurements.
Cardiac CT protocol
- ECG-gated acquisition with thin slices and adequate left-atrial contrast; use delayed imaging when early filling defect may represent slow flow.
- Reconstruct an en-face ostial plane and a device-specific landing-zone plane orthogonal to the centerline.
- Report Dmax, Dmin, mean diameter, perimeter, area, perimeter-derived diameter, area-derived diameter, depth, bend distance, lobe geometry, and predicted fluoroscopic angles.
- Inspect septal approach, IVC-to-septum relationship, pulmonary veins, LCx proximity, prior surgical exclusion, and extracardiac findings.
| Modality | Best use | Common failure | Correction |
|---|---|---|---|
| 2-D TEE | Dynamic sizing, thrombus assessment, puncture and live implant guidance | Off-axis undermeasurement; confusing ridge/limbus with ostial plane | Multiplane sweep, biplane/3-D confirmation, correlate with CT |
| CT | True 3-D geometry, perimeter/area, depth, trajectory and follow-up device assessment | Early-phase pseudo-thrombus; measuring an anatomically attractive but device-irrelevant plane | Delayed phase; device-specific reconstruction |
| ICE | Avoid GA/TEE, direct septal and device imaging from RA or LA | Incomplete LAA interrogation from a single position; catheter-related LA risk | Systematic multiposition protocol and operator-specific training |
| Fluoroscopy | Sheath/device mechanics, angiography, coaxiality, stability | Parallax and false impression of seal | Orthogonal projections plus echo/CT integration |
Device platforms: design drives technique
| Feature | WATCHMAN FLX / FLX Pro | Amplatzer Amulet |
|---|---|---|
| Architecture | Single-lobe nitinol frame with membrane; distal closed end; circumferential anchors. FLX Pro adds a thromboresistant polymer coating and broader size portfolio. | Distal lobe with stabilizing wires plus proximal disc connected by a waist. |
| Closure concept | Plug the appendage at a defined landing zone. | Anchor the lobe and cover the ostium with the disc. |
| Imaging emphasis | Position, anchor engagement, compression/conformation, seal, shoulder, depth. | Lobe axis and compression, separation from LCx/mitral apparatus, concave disc, complete ostial coverage. |
| Anatomic strengths | Recapturable/repositionable; broad contemporary evidence; favorable in many tubular or capacious appendages. | Ostial coverage can help shallow or complex ostia; lobe and disc treat landing zone and ostium separately. |
| Typical failure modes | Excessive shoulder, shallow anchor engagement, under/oversizing, noncoaxial deformation, residual gutter. | Proximal lobe, malaligned disc, disc inversion/prolapse, mitral/PV interaction, inadequate lobe compression. |
Exact size matrices, compression limits, sheath requirements, medication regimens, and release criteria are controlled by the current regional IFU. Use the current WATCHMAN professional resources and current Amulet professional resources; never substitute a remembered chart for the IFU.
Device selection is a geometry problem
- Prefer a platform whose fixation zone has adequate circumferential tissue and whose seal mechanism addresses the actual ostium.
- Do not choose a larger device merely to compensate for poor coaxiality or a wrong transseptal puncture.
- In shallow anatomy, distinguish insufficient true depth from an unfavorable sheath vector; they require different solutions.
- Consider future left-atrial access, combined procedures, nickel hypersensitivity history, renal/contrast limitations, and the required post-implant regimen.
Lab setup, anesthesia, access, and anticoagulation
Before venous puncture
Primary and assisting operator, imaging physician, anesthesia, scrub/circulator, and immediate CT surgical/pericardial rescue pathway.
Device sizes and sheaths, transseptal system, pigtail, stiff exchange wire, pericardiocentesis set, covered rescue options, snares, large-bore retrieval sheaths, protamine, blood availability.
Baseline BP, rhythm, hemoglobin, renal function, anticoagulant timing, volume status, allergy plan, and neurologic baseline.
Repeat thrombus check, pericardial survey, septal target, and device-specific measurements before crossing.
General anesthesia versus conscious sedation
GA offers controlled ventilation and stable TEE imaging but adds anesthesia exposure. Conscious sedation is feasible with ICE or selected TEE workflows and may shorten recovery. The correct choice is the one that preserves imaging quality, immobility during transseptal and release, airway safety, and immediate rescue capability.
Anticoagulation
Administer heparin before or immediately after transseptal crossing according to protocol and device training; monitor ACT throughout left-atrial dwell. Many programs target ACT ≥250 seconds, with some targeting 250–300 seconds. Re-dose based on measured ACT—not elapsed time alone. Meticulous continuous flush and de-airing are nonnegotiable.
Transseptal puncture: engineer the delivery vector
The “default inferior-posterior puncture” is a useful starting heuristic, not a universal answer. The ideal location creates a direct, controllable line from IVC to septum to landing zone while preserving sheath depth and avoiding excessive torque.
| Observed problem | Likely geometry | Implication |
|---|---|---|
| Sheath points above the ostium; device dives superiorly | Puncture too superior or insufficient inferior reach | Loss of usable depth; consider steerability, wire/lobe change, or repuncture |
| Sheath hugs anterior LA and crosses appendage obliquely | Puncture too anterior | Asymmetric compression/shoulder and unstable force vector |
| Posterior wall pressure with difficult anterior appendage reach | Puncture may be excessively posterior | High torque and wall interaction; reassess path before forceful advancement |
| Adequate measurements but device repeatedly appears shallow | Trajectory, not true depth, may be limiting | Correct coaxiality before downsizing |
Puncture sequence
- Define target in two orthogonal echo planes.Use bicaval for superior-inferior and short-axis for anterior-posterior position.
- Confirm tenting, not just needle location.Assess septal thickness, excursion, and relation to aortic root and posterior wall.
- Cross under continuous visualization.Confirm left-atrial entry before advancing dilator/sheath.
- Reassess the vector immediately.A successful puncture anatomically can still be a failed puncture procedurally.
Implant technique: from sheath entry to release
- Enter the LA safely.Maintain wire visualization, anticoagulation, continuous flush, and strict de-airing.
- Place the wire or pigtail deliberately.Choose a stable dominant lobe with adequate length; never blindly advance into a thin distal lobe.
- Acquire angiography without overpressurization.Use a projection that profiles the ostium and landing zone; reconcile contrast geometry with echo and CT.
- Reconfirm size under procedural loading conditions.LA pressure, rhythm, ventilation, and volume status can change measured dimensions.
- Deploy by controlling sheath and device as a coupled system.Avoid pushing the device out as an isolated maneuver. Preserve coaxiality and allow the frame/lobe to expand predictably.
- Assess every release criterion in orthogonal views.Use device-specific criteria, not an aesthetic judgment.
- Perform stability testing thoughtfully.The purpose is to confirm anchor engagement, not to prove that excessive traction cannot dislodge the implant.
- Release only after a deliberate team pause.Imager and operator verbally confirm position, fixation/compression, seal, neighboring structures, and no effusion.
- After release, image again.Confirm stability, residual flow, mitral and pulmonary-vein function, pericardium, and absence of new thrombus.
WATCHMAN: translate PASS into specifics
Device sits at the intended landing zone with acceptable shoulder and no harmful protrusion.
Stable fixation with appropriate anchor engagement and controlled tug response.
Compression/conformation falls within the current device-specific IFU across views.
No unacceptable residual jet; interrogate the entire circumference, not a single color sector.
Amulet: lobe and disc must both be correct
Confirm a compressed, properly oriented lobe with stable wire engagement; separation from LCx and mitral apparatus; a concave disc covering the ostium; appropriate relationship between lobe, waist, and disc; and no harmful pulmonary-vein or mitral interaction. If the disc looks excellent but the lobe is unstable, the implant is not acceptable.
Procedural troubleshooting by failure mechanism
Excessive shoulder or proximal device position
- Determine whether the cause is inadequate depth, too large a device, early frame opening, anterior/superior puncture, or off-axis sheath.
- Do not automatically downsize: a smaller device may worsen fixation if geometry is the real problem.
- Recapture, change wire/lobe, reshape the sheath vector, or repuncture when necessary.
Asymmetric compression / “mitral shoulder”
- Confirm whether one quadrant is constrained by the ridge, bend, or trabeculation.
- Use orthogonal echo and fluoroscopy; a favorable single profile can hide eccentricity.
- Differentiate safe shoulder from a gutter that creates residual communication or weak anchor engagement.
Shallow chicken-wing anatomy
- Measure bend distance, not just total depth. A proximal bend may prevent full device advancement.
- A more posterior/inferior vector, alternate lobe, different platform, or smaller device may help—but each changes fixation and seal.
- Avoid “straightening” the appendage with force.
Residual leak before release
- Map location, width, neck, and mechanism: undersizing, malalignment, incomplete expansion, trabecular channel, disc malapposition, or complex ostium.
- Optimize while the device remains recapturable. Do not accept a preventable leak because one view appears satisfactory.
Device will not recapture or sheath will not advance
- Stop force. Confirm coaxiality, remove excessive torque, assess anchor entanglement, and maintain imaging of the distal tip.
- Follow platform-specific partial/full recapture steps. Escalate early if deformation or tissue entrapment is suspected.
Complications: recognition, first actions, and rescue
| Event | Early clues | Immediate actions | Definitive questions |
|---|---|---|---|
| Perforation / tamponade | Hypotension, tachycardia, narrowing pulse pressure, new effusion, chamber collapse, electromechanical dissociation | Stop manipulation; call rescue; echo; fluids/blood; pericardiocentesis; reverse heparin when appropriate | Ongoing bleeding? Source—wire, sheath, transseptal, device? Need autotransfusion, surgery, or device removal? |
| Device embolization | Loss of expected device silhouette; unstable position; acute MR/LVOT/aortic obstruction; peripheral ischemia | Localize; maintain hemodynamics; avoid pushing device into a worse location; assemble snares/large sheath; call surgery | Location, orientation, size, valve interaction, retrievability, vascular exit strategy |
| Air embolism | Inferior ST elevation/RV dysfunction, neurologic deficit, abrupt hypotension | 100% O₂; aspirate from sheath/coronary if accessible; hemodynamic support; coronary angiography or stroke pathway | Source of air and whether cerebral/coronary intervention is required |
| Thromboembolism | Visible thrombus, ACT gap, neurologic or coronary event | Restore anticoagulation if safe; aspiration when accessible; activate stroke/coronary pathway | Air vs thrombus, bleeding constraint, large-vessel target |
| Acute mitral/PV interaction | New MR, pulmonary-vein flow change, disc/device impingement | Do not release; recapture/reposition or change device | Can geometry be corrected without compromising fixation? |
| Vascular bleeding | Groin swelling, flank pain, Hb drop, hypotension | Compression, ultrasound/CTA, transfusion/reversal as needed, vascular intervention | Venous site, arterial injury, retroperitoneal bleed, pseudoaneurysm |
Pericardial rescue discipline
- Recognize before profound shock: compare with baseline pericardial imaging.
- Drain under echo/fluoroscopy; send for blood salvage where supported.
- Reverse heparin after weighing active LA/device thrombotic risk.
- Leave the drain, trend output, and determine whether the source is self-limited or requires surgery.
- Document the exact causative step for quality review.
Post-implant antithrombotic therapy
The objective is to prevent device-related thrombus during endothelialization while minimizing the bleeding harm that motivated LAAC. There is no universally superior regimen across devices and phenotypes.
| Strategy | Evidence context | Best fit | Limitations |
|---|---|---|---|
| Short-term OAC + aspirin | Pivotal WATCHMAN pathway; DOAC-based practice increasingly used | Patient can tolerate finite anticoagulation; high concern for device thrombosis | Early bleeding; exact regimen and duration must follow label/protocol |
| DAPT | Amulet practice and contemporary WATCHMAN labeling/registries | OAC undesirable but antiplatelets feasible | Still causes bleeding; randomized comparisons with OAC remain limited |
| SAPT | Observational/high-bleeding-risk practice | Exceptional patients with major constraints | Knowledge gap 2025 guideline did not make a recommendation |
| No therapy | Very limited observational experience | Rare extreme bleeding scenario only | Potential DRT risk; requires individualized multidisciplinary decision |
A practical decision hierarchy
- Start with the current device IFU and the regimen supported by the implant strategy.
- Define the bleeding lesion: healed versus active, reversible versus persistent, intracranial versus GI, and whether aspirin is actually safer than a DOAC.
- Incorporate device result: deep/proximal position, residual leak, low-flow state, severe LA enlargement, spontaneous contrast, prior thrombus, hypercoagulability.
- Set a written stop/de-escalation date contingent on surveillance—not an indefinite default.
- If DRT develops, treat it as a new thrombotic event and revisit the original bleeding tradeoff.
Surveillance: device-related thrombus, peridevice leak, and CT findings
Follow-up imaging
TEE or cardiac CT is generally performed at approximately 45–90 days, with additional imaging dictated by device label, regimen, abnormal findings, or clinical events. CT may be more sensitive for residual patency and hypoattenuated thickening; TEE provides hemodynamic and dynamic assessment without iodinated contrast.
Device-related thrombus (DRT)
DRT occurs in roughly 3%–5% across many historical datasets, with variation by device, imaging schedule, definitions, and population. Associations include prior stroke, persistent/permanent AF, large LA/LAA, low LAA velocity, LV dysfunction, deep implant, incomplete seal, hypercoagulability, renal dysfunction, and off-protocol antithrombotic therapy. DRT is associated with increased embolic events but is not synonymous with inevitable stroke.
Peridevice leak (PDL)
- Characterize maximum width, circumferential extent, neck, location, jet direction, device depth, and whether CT shows distal appendage patency.
- The historical >5 mm threshold was used in pivotal WATCHMAN protocols, but observational data suggest even small leaks may carry incremental thromboembolic risk.
- Management is not standardized. Options include continued OAC, surveillance, leak closure with plug/coils, or repeat appendage intervention depending on size, mechanism, events, and bleeding tolerance.
- Do not label a leak “benign” solely because it is below a legacy threshold.
Hypoattenuated thickening on CT
Differentiate benign healing-related low-grade thickening from protruding or high-grade HAT consistent with DRT. Interpret CT morphology, location, protrusion, contrast density, and interval change in the context of therapy and clinical events.
Evidence base: what the trials actually establish
PROTECT AF · 707 patients
Lancet 2009; JAMA 2014First pivotal randomized comparison of WATCHMAN with warfarin (2:1). It established proof of efficacy but had an early procedural safety penalty during the first-generation learning curve. Later follow-up supported noninferiority/superiority analyses for composite outcomes.
Interpretation: foundational efficacy evidence, but device, operator experience, and antithrombotic care differ markedly from current practice.PREVAIL · 407 patients
JACC 2014Designed to confirm PROTECT AF with improved procedural safety. One primary efficacy noninferiority endpoint was not met, influenced by unexpectedly low warfarin-control event rates; the later ischemic endpoint met noninferiority.
Interpretation: do not describe PREVAIL simply as a uniformly “positive” trial.PROTECT AF + PREVAIL pooled 5-year outcomes · 1,114 patients
JACC 2017Stroke/systemic embolism was broadly similar; LAAC reduced hemorrhagic stroke, disabling/fatal stroke, cardiovascular/unexplained death, all-cause death, and post-procedure bleeding compared with warfarin. The ischemic stroke/SE point estimate favored warfarin, while bleeding and mortality favored LAAC.
Interpretation: benefit emerges through avoidance of hemorrhagic and late bleeding events, not clear superiority for ischemic stroke prevention.ASAP · 150 patients
JACC 2013Prospective nonrandomized WATCHMAN study in patients considered ineligible for warfarin using antiplatelet-based therapy. Observed ischemic stroke was approximately 1.7% per year versus a substantially higher score-predicted rate.
Interpretation: important feasibility signal; not randomized and expected-rate comparison can exaggerate apparent benefit.EWOLUTION · 1,025 patients
Heart Rhythm 2017International real-world WATCHMAN registry with high implant success, ischemic stroke around 1.1% at 1 year, and DRT around 3.7%, despite most patients being unsuitable for long-term OAC.
Interpretation: supports generalizability and varied post-implant regimens; registry confounding remains.PRAGUE-17 · 402 patients
JACC 2020; 4-year 2022High-risk patients randomized to LAAC or DOAC (predominantly apixaban). LAAC was noninferior for a composite of cardiovascular death, stroke/TIA, systemic embolism, clinically significant bleeding, and device/procedural complications. Longer follow-up showed less nonprocedural clinically relevant bleeding with LAAC.
Interpretation: strongest randomized evidence against contemporary DOAC therapy before OPTION, but modest sample size and composite endpoint matter.PINNACLE FLX · 400 patients
Circulation 2021; JAHA 2023Prospective single-arm study of WATCHMAN FLX: 98.8% implant success; all patients with evaluable 1-year imaging had residual jet ≤5 mm; DRT occurred in 7 patients. Two-year data showed no additional DRT or systemic embolism after year 1.
Interpretation: validates platform performance and seal, but lacks a randomized comparator.Amulet IDE · 1,878 patients
Circulation 2021Randomized Amulet versus first-generation WATCHMAN. Amulet was noninferior for safety and effectiveness and achieved more complete occlusion at 45 days (98.9% vs 96.8%), with more procedure-related complications in the Amulet arm during the study era.
Interpretation: better anatomic closure does not automatically translate into demonstrated clinical superiority.SWISS-APERO · 221 patients
Circulation 2022Randomized Amulet versus WATCHMAN 2.5/FLX with CT follow-up. The primary CT patency endpoint was not significantly different, while procedural and imaging findings illustrated that “closure” varies by modality and definition.
Interpretation: CT detects residual patency not always appreciated by color Doppler alone.OPTION · 1,600 patients after AF ablation
NEJM 2024WATCHMAN FLX was compared with OAC after ablation. At 36 months, nonprocedural major or clinically relevant nonmajor bleeding was 8.5% with LAAC versus 18.1% with OAC; death/stroke/systemic embolism was 5.3% versus 5.8%, meeting noninferiority. Device/procedure complications occurred in 3.9%.
Interpretation: supports LAAC as an alternative after ablation in trial-eligible patients; it does not justify stopping OAC solely because ablation appears successful.How a fellow should critique any LAAC study
- What is the comparator—warfarin, DOAC, no therapy, or another device?
- Is the endpoint clinical, imaging-based, or a composite that mixes procedural harm with late benefit?
- Was the device current generation, and were operators in the learning curve?
- What therapy was required in the device arm, and for how long?
- Were analyses intention-to-treat, per-protocol, or as-treated?
- How large was the noninferiority margin, and was the control event rate as expected?
- Did the trial enroll the patient phenotype in front of you?
Unresolved controversies and research frontiers
PRAGUE-17 and OPTION are supportive in selected populations, but broader first-line substitution awaits mature large-strategy evidence and careful lifetime-risk analysis.
OAC versus DAPT is guideline-supported as a choice, but optimal drug, intensity, and duration for specific devices and bleeding phenotypes remain uncertain.
Observational signal exists; causal risk, thresholds, and whether closing the leak improves outcomes remain unproven.
CT increases sensitivity for patency and HAT, but standard definitions and treatment thresholds are still evolving.
OPTION supports selected patients; same-session workflow may reduce access episodes but adds procedure duration, anticoagulation complexity, and edema-related imaging issues.
Residual stumps/leaks after ligation or clip require individualized CT/TEE definition; evidence for percutaneous completion is mainly observational.
The patients most in need of a nonpharmacologic strategy may be least able to tolerate the therapy required for safe endothelialization.
Young patients raise questions about decades of device interaction, future transseptal access, repeat procedures, and stroke mechanisms beyond the LAA.
Primary literature and authoritative guidance
- 2023 ACC/AHA/ACCP/HRS Guideline for Diagnosis and Management of Atrial Fibrillation.
- 2025 SCAI/HRS Clinical Practice Guidelines on Transcatheter LAAC.
- SCAI/HRS Expert Consensus Statement on Transcatheter LAAC (2023).
- PROTECT AF: percutaneous LAA closure versus warfarin.
- PREVAIL randomized trial.
- Five-year outcomes from PREVAIL and PROTECT AF.
- ASAP: WATCHMAN in patients with contraindication to oral anticoagulation.
- EWOLUTION peri-procedural outcomes.
- PRAGUE-17: LAAC versus direct oral anticoagulants.
- PRAGUE-17 four-year outcomes.
- PINNACLE FLX primary outcomes.
- Amulet IDE randomized trial.
- SWISS-APERO randomized comparison with CT assessment.
- OPTION: LAA closure after AF ablation.
- Impact of peridevice leak on five-year outcomes after LAAC.